Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles by Hedberg-Oldfors, Carola et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2020-08-01 
Loss of supervillin causes myopathy with myofibrillar 
disorganization and autophagic vacuoles 
Carola Hedberg-Oldfors 
University of Gothenburg 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Cardiovascular Diseases Commons, Cell 
Biology Commons, Cellular and Molecular Physiology Commons, Molecular and Cellular Neuroscience 
Commons, Musculoskeletal Diseases Commons, Musculoskeletal, Neural, and Ocular Physiology 
Commons, Nervous System Diseases Commons, and the Neurology Commons 
Repository Citation 
Hedberg-Oldfors C, Luna EJ, Oldfors A, Knopp C. (2020). Loss of supervillin causes myopathy with 
myofibrillar disorganization and autophagic vacuoles. Open Access Articles. https://doi.org/10.1093/
brain/awaa206. Retrieved from https://escholarship.umassmed.edu/oapubs/4320 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Loss of supervillin causes myopathy with
myofibrillar disorganization and
autophagic vacuoles
Carola Hedberg-Oldfors,1,* Robert Meyer,2,* Kay Nolte,3,* Yassir Abdul Rahim,1
Christopher Lindberg,4 Kristjan Karason,5 Inger Johanne Thuestad,6 Kittichate Visuttijai,1
Mats Geijer,7,8 Matthias Begemann,2 Florian Kraft,2 Eva Lausberg,2 Lea Hitpass,9
Rebekka Götzl,10 Elizabeth J. Luna,11 Hanns Lochmüller,12,13 Steffen Koschmieder,14
Michael Gramlich,15 Burkhard Gess,16 Miriam Elbracht,2 Joachim Weis,3 Ingo Kurth,2
Anders Oldfors1 and Cordula Knopp2
*These authors contributed equally to this work.
The muscle specific isoform of the supervillin protein (SV2), encoded by the SVIL gene, is a large sarcolemmal myosin II- and F-
actin-binding protein. Supervillin (SV2) binds and co-localizes with costameric dystrophin and binds nebulin, potentially attaching
the sarcolemma to myofibrillar Z-lines. Despite its important role in muscle cell physiology suggested by various in vitro studies,
there are so far no reports of any human disease caused by SVIL mutations. We here report four patients from two unrelated, con-
sanguineous families with a childhood/adolescence onset of a myopathy associated with homozygous loss-of-function mutations in
SVIL. Wide neck, anteverted shoulders and prominent trapezius muscles together with variable contractures were characteristic fea-
tures. All patients showed increased levels of serum creatine kinase but no or minor muscle weakness. Mild cardiac manifestations
were observed. Muscle biopsies showed complete loss of large supervillin isoforms in muscle fibres by western blot and immunohis-
tochemical analyses. Light and electron microscopic investigations revealed a structural myopathy with numerous lobulated muscle
fibres and considerable myofibrillar alterations with a coarse and irregular intermyofibrillar network. Autophagic vacuoles, as well
as frequent and extensive deposits of lipoproteins, including immature lipofuscin, were observed. Several sarcolemma-associated
proteins, including dystrophin and sarcoglycans, were partially mis-localized. The results demonstrate the importance of the super-
villin (SV2) protein for the structural integrity of muscle fibres in humans and show that recessive loss-of-function mutations in
SVIL cause a distinctive and novel myopathy.
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Introduction
Supervillin, encoded by the SVIL gene, is a large eukaryotic
protein from the villin/gelsolin superfamily of actin-binding
proteins (Pestonjamasp et al., 1997) that is involved in many
cellular processes. Among others, supervillin regulates cyto-
kinesis (Smith et al., 2010, 2013), cell adhesion (Takizawa
et al., 2006) and cell motility (Fang et al., 2010) and pro-
motes cell survival through control of p53 levels (Fang and
Luna, 2013). Supervillin mRNAs are expressed in most
human tissues, but are most abundant in skeletal muscle, fol-
lowed by the heart and organs containing secretory or
smooth muscle cells (Pope et al., 1998). In cardiac and skel-
etal muscle, the 250-kDa muscle-specific isoform of supervil-
lin (SV2), also called archvillin, is predominantly expressed
(Pope et al., 1998; Oh et al., 2003; Fang and Luna, 2013).
Supervillin (SV2) is localized at the ends of differentiating
myotubes (Oh et al., 2003) and plays a role in myofibrillar
assembly (Lee et al., 2007). There is evidence for co-localiza-
tion and interaction of supervillin (SV2) with structural pro-
teins in costameres and sarcomeres, which are important
components of cardiac and skeletal muscle cells (Oh et al.,
2003; Lee et al., 2007, 2008; Spinazzola et al., 2015).
Among others, there are interactions with nebulin, dystroph-
in and c-sarcoglycan, for which distinct and often severe
human muscular disorders are well known. For example,
mutations in nebulin account for about 50% of patients
with congenital nemaline myopathy (Romero and Clarke,
2013). Genetic variants in costameric proteins, such as dys-
trophin, cause cardiac and skeletal muscle disorders (Nigro
and Piluso, 2015). Mutations in components of the sarcogly-
can complex likewise cause limb-girdle muscular dystro-
phies, which are variably associated with cardiomyopathy
(Jaka et al., 2015).
Despite the interaction of supervillin (SV2) with costa-
meric and sarcomeric proteins, no muscular disease associ-
ated with SVIL mutations has so far been described. Here,
we report four patients from two unrelated families with
homozygous loss-of-function mutations in SVIL. The
patients presented with myopathy and mild cardiac involve-
ment and share a characteristic muscle pathology with lobu-
lated fibres and other structural abnormalities.
Material and methods
Patients and clinical evaluation
Two families with two affected siblings with myopathy, re-
spectively, were investigated clinically, morphologically and
genetically. Family 1 originates from Lebanon and Family 2
from Turkey. The study complied with the Declaration of
Helsinki, and informed consent was obtained from all indi-
viduals included in this study. Medical history taking and
physical examination were focused on neuromuscular and
cardiac symptoms and signs. A summarized overview of the
clinical phenotypes of all four patients is provided in
Table 1.
Muscle MRI
Magnetic resonance examinations were performed in all
four patients according to protocols described in the
Supplementary material.
Morphological analysis
Skeletal muscle biopsy was performed in all four patients.
Specimens were snap-frozen in liquid propane chilled with li-
quid nitrogen for cryostat sectioning and histochemistry,
and fixed in buffered glutaraldehyde for electron micros-
copy. Standard techniques were used for enzyme histochem-
istry, immunohistochemistry and electron microscopy
(Dubowitz et al., 2013). For immunohistochemistry investi-
gations, fresh frozen sections were incubated with primary
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antibodies according to Supplementary Table 1A. Controls
used in this study included muscle biopsies from age-
matched individuals, investigated for muscle complaints but
in whom the investigations excluded a muscle disease.
Molecular genetic analysis
For Family 1, exome sequencing target enrichment was per-
formed on genomic DNA from Patients III:1 and III:5 using
the Sure SelectXT Human All Exon kit version 6 (Agilent
Technologies), with sequencing on the HiSeq4000 platform
(Illumina). The paired-end reads were aligned to the refer-
ence genome (hg19). Based on the assumption of a recessive
inherited disease a search for potential compound heterozy-
gous or homozygous variants in genes possible to be associ-
ated with myopathy was performed. Population frequencies
were estimated using the genome aggregation database
(gnomAD), last accessed in June 2019. The Combined
Annotation-Dependent Depletion (CADD) tool (version
v1.4) was used as an in silico prediction algorithm to predict
the pathogenicity of the variants identified. Variants with
CADD scores 420 with allele frequencies 51% were eval-
uated further. Candidate variants were confirmed by Sanger
sequencing and segregation studies were performed with
available DNA samples.
For RNA studies, total RNA was isolated from frozen
skeletal muscle from Patients III : 1 and III : 5 using the
RNeasyV
R
Fibrous Tissue Mini Kit (Qiagen). RNA was re-
verse transcribed with the QuantiTect reverse transcription
kit (Qiagen), and cDNA was analysed by PCR and Sanger
sequencing. The forward and reverse primers were designed
to hybridize to different exons that were separated by large
Table 1 Clinical phenotypes and results from laboratory investigations in the patients
Family 1 Country of origin: Lebanon Family 2 Country of origin: Turkey
Patient III:1 Patient III:5 Patient III:2 Patient III:3
Gender Male Male Female Male
Age at onset/last
examination
Childhood/27 years Adolescence/17 years At birth/41 years Infancy/34 years
Initial symptoms Thin muscles particularly lower legs
since childhood
Increased fatigue at exercise Congenital contractures of hips
and elbows
Tiptoe walking in infancy
Clinical complaints Between 20 to 24 years of age
episodic weakness, muscle pain and
muscle fatigue at exercise; since
then asymptomatic
Increased fatigue at exercise Muscle pain (neck and shoulders),
muscular cramps (lower legs,
feet), painful cramping when
remaining in the same position
for long
Muscular cramps (lower legs, feet),
painful cramping when remaining
in the same position for long,
mild weakness when working
above head height
Clinical examination
Physical signs Wide neck, anteverted shoulders,
prominent trapezius and latissimus
dorsi muscles, thin lower legs,
slight syndactyly between fingers,
sandal gap
Wide neck, muscles of
extremities hypertrophic
proximal compared to distal,
hypertrophic lumbar back
muscles, mild syndactyly
between fingers, sandal gap
Wide neck and malposition of
shoulder girdle (hypertrophic




Wide neck and malposition of
shoulder girdle (hypertrophic




Contractures Long finger flexors, slight shortening
of Achilles tendons
None Knee, ankles, elbow, fingers Knee, ankles, elbow, fingers
Percussion myotonia NA NA Deltoid and biceps bracchii
muscle
Deltoid and biceps bracchii muscle
Muscle strength Normal Normal Normal Normal
Further examination
NCV Normal Normal Normal Normal
EMG Myopathic in quadriceps muscle,
normal in deltoid and interosseous
dorsi muscles
Myopathic Normal in deltoid muscle Normal in deltoid muscle
Whole-body MRI Normal muscular structure Normal muscular structure Normal muscular structure Normal muscular structure
ECG Q waves in aVL, I and –aVR,
T-inversions in aVF and 3, increased
QRS amplitudes
Tendency towards left ventricular
hypertrophy
Prolonged QTc-time (501 ms) T-inversions in aVF and 3
Holter-ECG Normal NA Normal NA




Slightly hypertrophic left ventricular
wall, slight tricuspid regurgitation
Cardio-MRI Increased basal wall thickness Normal Normal Normal
Creatine kinase 3  UNR 2-4  UNR 2–3  UNR 2  UNR
Troponin T (ref. val.
5 14 ng/l)




NA NA Normal Normal
Muscle biopsy Structural myopathy with prominent lobulated type 1 fibres, myofibrillar disintegration and signs of altered proteostasis/impaired autophagy
DNA analysis c.4812C4A (hom) c.4812C4A (hom) c.3578_3579del (hom) c.3578_3579del (hom)
Protein change p.Tyr1604* p.Tyr1604* p.Val1193Glufs*46 p.Val1193Glufs*46
hom = homozygous; NA = not assessed; UNR = upper normal range.
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introns to generate a specific PCR-product on cDNA
(Supplementary Fig. 1B and C). Primer sequences and PCR
conditions are described in the Supplementary material.
For Family 2, exome sequencing was performed with the
DNA from peripheral blood of Patients III:2 and III:3.
Enrichment was done with an Illumina Enrichment Kit
(Nextera Rapid Capture Exome v1.2). The exome library
was sequenced on a NextSeq500 Sequencer with 2  75
cycles. FastQ files were generated with bcl2fastq2 (Illumina,
San Diego, CA, USA). Primary alignment, indel realignment
and variant calling were performed by using an in-house
pipeline based on SeqMule (Guo et al., 2015). Variant call-
ing was done by three different variant callers (GATKLite,
SAMtools, FreeBayes). Genome version hg19 was used for
the alignment. Only variants called by at least two variant
callers were included in the final variant file. Average cover-
age in the target region was 80 (Patient III:2)/89
(Patient III:3), with 89% (Patient III : 2)/91% (Patient III:3)
above 20 coverage. For variant annotation and prioritiza-
tion of variants KGGSeq was used (Li et al., 2012).
Synonymous variants and variants with a minor allele fre-
quency (MAF) higher than 0.75% in public databases (i.e.
gnomAD, ExAC, 1000 Genomes Project, ESP) were
excluded from further analysis.
Based on known consanguinity of the parents, homozy-
gous variants were prioritized for investigation of the exome
sequencing data. The remaining 17 homozygous variants
shared by both siblings were filtered for potential loss-of-
function, putative splicing variants and missense variants
that were predicted to be probably pathogenic using differ-
ent tools (CADD, PolyPhen, MutationTaster). Only putative
loss of function variants and variants with a CADD score
higher than 20 were kept. Variants were confirmed by
Sanger sequencing on a 3500 Genetic Analyzer platform
(Applied Biosystems). Segregation analysis was performed in
the mother, whereas DNA of the father was not available
for further testing.
Western blot
For Family 1, western blot was performed on protein
extracted from cryostat sections of muscle biopsy specimens
from both patients (Patients III:1 and III:5). The superna-
tants (including protein) were loaded and separated on a 3
to 8% Tris-Acetate gel (Novex; Life Technologies), followed
by electroblotting. The membranes were incubated with two
different antibodies against human supervillin (anti-SVIL;
Atlas antibodies; HPA020138, 1:500, epitope in the middle
part of the protein aa 847-984; CPTC-SVIL-3, 1:10, epitope
in the N-terminus of the protein amino acids 1–220) as pri-
mary antibodies. The epitopes of these antibodies are located
N-terminal to the location of the identified mutation. The
SuperSignalTM West Femto Maximum Sensitivity Substrate
(Life Technologies) was used for antibody detection.
For Family 2, western blot was performed on protein
extracted from a fresh frozen piece of the deltoid muscle
from both patients (Patients III:2 and III:3) using T-PER
buffer (Pierce). The lysates were subjected to SDS-polyacryl-
amide gel electrophoresis (PAGE) under reducing conditions
and transferred to polyvinylidene difluoride-membranes
(Millipore). The blots were incubated with the appropriate
antibody in TBS-T containing 3% BSA overnight at 4C, re-
spectively. Primary antibodies and dilutions are listed in
Supplementary Table 1B. Controls used in this study
included muscle biopsies from age-matched individuals,
investigated for muscle complaints but in whom the investi-
gations excluded a muscle disease. An extended protocol can
be found in the Supplementary material.
Data availability




Patient III:1 in Family 1 was a 27-year-old male and first
child of consanguineous healthy parents (first degree cous-
ins) of Lebanese ancestry. Since childhood, he has had thin
muscles especially affecting the lower legs without apparent
weakness. Between 20 and 24 years of age, he had experi-
enced episodic muscle pain, weakness and fatigue. These epi-
sodes were most evident in his arms and legs in the
beginning of the day, lasting from one month to several
months and without any apparent triggering or associated
factors. Neurological examination at age 27 revealed no
muscle weakness, but the lower legs were thin, the medial
parts of the gastrocnemius muscles were atrophic (Fig. 1).
He had a wide neck, anteverted shoulders, prominent trapez-
ius and latissimus dorsi muscles and a tendency to thoracic
kyphosis. He had slight shortening of the Achilles tendons,
and slight contractures of his long finger flexors. Slight syn-
dactyly was observed between fingers and a tendency to san-
dal gap widening between the first and second toe. EMG of
the vastus lateralis was borderline myopathic as found on
the turns amplitude analysis of the interference pattern.
EMG was normal in the deltoid muscle and the interosseus
dorsi muscles of the hands. At age 20 years, he was exam-
ined because of recurrent sharp chest pains. His ECG
showed Q waves in aVL, I and aVR, T-inversions in aVF
and III and increased QRS amplitudes in the chest leads,
suggesting left ventricular hypertrophy. A cardiopulmonary
exercise test (CPET) was prematurely terminated due to leg
fatigue and showed reduced exercise capacity, 192 W, 70%
of the reference value. Twenty-four-hour Holter monitoring
and echocardiography were normal. A cardiac MRI (CMR)
at age 27 showed increased basal wall thickness (30 mm)
consistent with hypertrophy and a small ventricular diver-
ticulum, but otherwise adequate systolic ventricular perform-
ance and normal valvular function. There were no signs of
atrial abnormalities.








enter Library user on 17 Septem
ber 2020
Laboratory tests revealed a persistent increase in high-sen-
sitive cardiac troponin T 20–30 ng/l (reference value 514
ng/l), serum creatine kinase (CK) 18–22 lkat/l (reference
interval 0.80–6.7 lkat/l), CK-MB 32–36 lg/l (reference
value 55 lg/l) and myoglobulin 178 lg/l (reference value
590 lg/l). N-terminal prohormone of brain natriuretic pep-
tide (NT-proBNP) was normal 130–250 ng/l (reference value
5300 ng/l).
MRI showed a symmetrical representation of all
muscles. In the right semimembranosus muscle, there was
a marked high signal on the fat-suppressed T2-weighted
sequence representing oedema, with a slight fatty infiltra-
tion in the medial half of the muscle. On the left, there
was a superficial marginal oedema in the same muscle
without fatty infiltration. Otherwise, no evidence of intra-
muscular oedema or fatty degeneration could be found.
The distribution of the muscle bulk corresponded with the
clinical assessment, and there were no signs of fatty re-
placement of the relatively thin muscles of the lower legs
and distal arms.
Figure 1 Clinical picture of Family 1. (A–D) Patient III:5. (E–H) Patient III:1. (A and B) Hypertrophic trapezius muscles and wide neck.
Limb muscles are hypertrophic proximally as compared to distally in both arms and legs and the lumbar back muscles are prominent. (C and D)
Syndactyly is present between all fingers and the feet show sandal gap sign. (E) Wide neck, anteverted shoulders, prominent trapezius and latissi-
mus dorsi muscles and a tendency to thoracic kyphosis. (F) The lower legs are thin with reduced size of the medial parts of the gastrocnemius
muscles and a tendency to sandal gap widening between the first and second toe. (G and H) Slight syndactyly is present between fingers and
slight contractures of the long finger flexors.
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Patient III:5 was a 17-year-old male and the younger
brother of Patient III:1. Since age 12 years he had experienced
increased fatigue and shortness of breath at exercise. At age
13 years he experienced an episode of syncope during physic-
al activity. He complained of chest pains, and ECG showed a
tendency towards left ventricular hypertrophy, which was
confirmed by echocardiography, showing a slightly hyper-
trophic left ventricular wall. A subsequent cardiac MRI
showed a normal size of the heart chambers and normal func-
tion. No cardiac fibrosis was seen. Later, ergometry and spir-
ometry showed normal results. Blood tests showed elevated
levels of troponin T; 134, 158, 72, 50 ng/l (reference value
515 ng/l) measured over the course of 3 days, and later at
follow-up 13 and 31 ng/l. NT-proBNP at corresponding dates
measured 142, 183, 285 and 80 ng/l (reference value 5100
ng/l) and later at follow-up 65 and 90 ng/l. The serum creat-
ine kinase level was continuously slightly elevated, 15-30
lkat/l (reference interval 0.80–6.7 lkat/l).
Neurological examination showed no joint contractures.
His neck was wide and the proximal limb muscles were found
to be hypertrophic as compared to the distal ones in both arms
and legs (Fig. 1). The lumbar back muscles were also hyper-
trophic. Mild syndactyly was found between all fingers and his
feet showed sandal gap sign. Muscle strength was normal in
all muscle groups, though he was somewhat slower than
expected for his age in the 6-min walk test. The deep tendon
reflexes were absent in the arms, whereas they were normal in
the legs, without any apparent explanation for the discrep-
ancy. The facial muscles were unaffected. EMG indicated my-
opathy, and nerve conduction studies were normal.
MRI of the muscles in the limbs, thorax, abdomen, and pel-
vis showed normal muscle structure. MRI showed a symmet-
rical representation of all muscles without circumscribed
atrophies. No evidence of intramuscular oedema or fatty de-
generation could be found. The thigh muscles were better
developed than the muscles in the lower legs corresponding
with the clinical picture. The dorsal shoulder musculature was
hypertrophic, also corresponding with the clinical assessment.
Family 2
The index patient (Patient III:2), a 41-year-old female,
showed dysmorphism of the neck and shoulders in combin-
ation with muscular rigidity and myalgia (Fig. 2). She was
the first child of consanguineous healthy parents (first-degree
cousins) of Turkish origin. Her younger 34-year-old brother
(and only sibling) (Patient III:3) (Fig. 2) was similarly
affected while her 11-year-old daughter was healthy. Further
family history was unremarkable; there were no further fam-
ily members affected by neuromuscular disorders.
Both patients presented with a history of a neuromuscular
disorder. The female patient reported congenital contractures
of the hips and elbows while her brother reported tiptoe
walking in infancy as the initial symptom. No significant
delay in achieving motor milestones was reported and cogni-
tive function was normal. Both patients had received physio-
therapy since infancy. At the time of first presentation at our
clinic at the age of 41 (Patient III:2) and 34 (Patient III:3)
years, respectively, they complained about muscle pain espe-
cially of the neck and shoulders, muscle cramps predomin-
antly affecting the lower legs and feet as well as painful
cramping when remaining in the same position for long.
Both patients described slowly progressive muscular rigidity
and contractures leading to pain and limited mobility.
Figure 2 Clinical picture of Family 2. (A, B and F) Patient
III:2. (C–E and G) Patient III:3. Wide neck due to hypertrophic M.
trapezius, malposition of shoulder girdle with anteverted shoulders,
hyperkyphosis (A–D), limited range of motion and contractures of
elbows (E), contractures of long finger flexors (F) and contractures
of knees and Achilles tendons (G).
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However, motor strength has remained stable in both
patients until today. In early adulthood, both patients under-
went mandibular osteotomy of jawbone because of man-
dibular protrusion.
On physical examination both patients showed a broad
neck and malposition of shoulder girdle including a hyper-
trophic and rigid trapezius muscle, anteverted shoulders and
a hyperkyphosis of the thoracic spine accompanied by a lim-
ited range of motion (Fig. 2). Furthermore, there were bilat-
eral contractures of the elbows, the long finger flexors
(female 4 male), the knees and the Achilles tendons.
Clinical examination did not reveal any obvious reduction
of muscle strength. There was no facial weakness, ptosis or
ophthalmoplegia. Bilateral percussion myotonia in the area
of the deltoid and biceps brachii muscles was present in
both patients (male 4 female). No rippling was observed.
There were no myotonic reactions noticeable in further body
regions. The deep tendon reflexes were normal.
Laboratory examination showed mildly elevated CK levels
in both patients (Patient III:2: 4.8–5.8 lkat/l, Patient III:3:
5.3–5.5 lkat/l, reference value 52.8 lkat/l). Nerve conduc-
tion studies and electromyography revealed no irregularities
in the patients. X-ray of the cervical and thoracic spine
revealed a diminished lordosis of the cervical spine and an
enhanced kyphosis and scoliosis of the thoracic spine in the fe-
male patient. Whole-body MRI focusing on the muscular
anatomy showed a low and unspecific signal increase in the
medial gastrocnemius head as well as in the left distal soleus
muscle in Patient III:2. These MRI signal alterations were
judged as unspecific, as they appear relatively commonly in
these muscles without clinical significance and Patient III:2
had no clinical symptoms in leg function and force.
Otherwise, MRI examinations of both siblings showed a sym-
metrical representation of all muscles without circumscribed
atrophies. No evidence of intramuscular oedema or fatty de-
generation could be found.
In the male patient, echocardiography showed a slightly
hypertrophic left ventricular wall, but cardiac MRI did not
show any structural cardiac involvement in either of the
patients. However, in the female patient, ECG and Holter-
ECG revealed a prolonged QT interval (QTc 501 ms); the
patient did not take any medication. High-sensitive cardiac
troponin T was normal in the male patient (8 ng/l) and
slightly above the reference value in the female patient (15
ng/l, reference value 5 14 ng/l). NT-proBNP was elevated
in both patients (female patient 935 pg/ml, reference value
5130 pg/ml; male patient 312 pg/ml, reference value 586
pg/ml). A comprehensive investigation of haemostasis and
coagulation was normal in both patients.
Muscle histopathology
Family 1
Muscle biopsy showed structurally altered muscle fibres in
both siblings, with coarse and irregular intermyofibrillar net-
work and some ring fibres. In multiple regions groups of
muscle fibres showed small vacuoles and internal nuclei.
Occasional rimmed vacuoles were observed and also groups
of fibres with protein aggregates in Patient III:1 (Fig. 3A and
B). Many fibres were lobulated, which was the most appar-
ent change (Fig. 3C). By electron microscopy, the vacuoles,
some of which appeared as invaginations, were partly delim-
ited by a sarcolemma-like membrane, but most appeared as
autophagic vacuoles with cellular debris (Fig. 3D). Groups
of fibres demonstrated Z-disc alterations with flag-like
extensions and more widespread protein aggregates (Fig. 3E
and F). By immunohistochemistry, vacuoles contained sarco-
lemma-associated proteins, such as a-sarcoglycan (Fig. 4A).
Caveolin-3 marked some of the vacuoles and also showed a
diffuse cytoplasmic immunoreactivity in occasional fibres, al-
though the overall immunohistochemical staining was vari-
ably reduced, especially in the elder brother (Fig. 4B).
Dystrophin was partly internalized (Fig. 4C) and desmin
appeared to be partly accumulated, especially in the subsar-
colemmal regions (Fig. 4D). Markers of autophagocytosis,
lysosomal associated membrane protein 2 (LAMP2) and
microtubule-associated protein 1A/1B-light chain 3 (LC3),
were upregulated in some fibres (Fig. 4E and F). Staining for
supervillin using the CPTC-SVIL-3 antibody from the
Developmental Studies Hybridoma Bank (DSHB) showed a
weak positive staining localized mainly to the sarcolemmal
region in controls but was completely absent in both broth-
ers (Fig. 4G).
Family 2
In both siblings, the muscle biopsy showed a moderately
broadened muscle fibre calibre spectrum with numerous par-
tially atrophic muscle fibres with diameters between 20 and
35 mm, but rarely less than 10 mm. There were no clearly
hypertrophic muscle fibres (Fig. 5A). The partially atrophic
muscle fibres had septa-like constrictions originating from
the sarcolemma, which gave these fibres a lobulated profile,
and there was prominent oxidative enzyme activity in these
fibres (Fig. 5B). In addition, some muscle fibres had cushion-
shaped, partially cap-like subsarcolemmal basophilic zones
with granular content. ATPase reaction revealed that the
partially atrophic, lobulated muscle fibres were almost exclu-
sively of fibre type 1 (Fig. 5C). There was no evidence of
necrotic muscle fibres. By electron microscopy, myofibrillary
alterations of varying degree could be seen in several muscle
fibres. Sarcoplasmic masses were frequently observed,
including non-membrane-bound glycogen, mitochondria,
and autophagic material (Fig. 5D). Several muscle fibres
showed a subsarcolemmal accumulation of non-enlarged
mitochondria. Accumulations of circumscribed granular or
globoid deposits were frequent, probably consisting of im-
mature lipofuscin and other lipoprotein deposits (Fig. 5E).
Rarely, mature nemalin rods were observed (Fig. 5F and G).
By immunohistochemistry, a-sarcoglycan appeared focally
accumulated in the subsarcolemmal region and also internal-
ly in several fibres (Fig. 6A). Reduced caveolin-3 staining
was observed in many fibres, especially small ones (Fig. 6B).
Dysferlin was atypically present in non-sarcolemmal struc-
tures in some fibres (Fig. 6C), and desmin was focally
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accumulated (Fig. 6D). There was subsarcolemmal accumu-
lation of LC3 immunoreactivity and internal LC3-positive
granular and vacuolar structures were also present in differ-
ent muscle fibres (Fig. 6E and F). Sequestosome 1 (p62) was
present under the sarcolemma in lobulated fibres and in
autophagic vacuoles (Fig. 6G).
Molecular genetic analysis and
western blotting
All affected patients from both families shared rare homo-
zygous mutations in the supervillin gene (SVIL; OMIM:
*604126, transcript NM_021738.2). Family 1 harboured a
nonsense mutation in exon 26, c.4812C4A; p.Tyr1604*,
which was not reported in genome databases (i.e. ExAC,
gnomAD, 1000 Genomes Project, dbSNP151, ESP)
(Fig. 7A, C and Supplementary Fig. 1A). Expression ana-
lysis of SVIL cDNA from skeletal muscle of Patients III:1
and III:5 from Family 1 showed lower SVIL transcript lev-
els in the patient samples relative to control samples
(Supplementary Fig. 1B and C). This result suggests that
the transcripts were to a large extent degraded by non-
sense-mediated mRNA decay, as expected by the introduc-
tion of a premature stop codon.
Figure 3 Biopsy from the vastus lateralis muscle of Patient III:1 in Family 1, as visualized by light (A–C) and electron micros-
copy (D–F). (A) Marked structural changes in groups of muscle fibres with internalized nuclei, eosinophilic protein aggregates (arrows) and mul-
tiple small vacuoles (arrowheads) (haematoxylin and eosin). (B) Some protein aggregates are purple in Gomori trichrome staining and others are
dark green (arrows). (C) The intermyofibrillar network is deranged and partly unusually coarse (arrows). Many fibres appear lobulated which
was the overall major alteration in the muscle biopsy (nicotinamide adenine dinucleotide tetrazolium reductase, NADH-TR). (D) In groups of
muscle fibres, there are numerous autophagic vacuoles with membranous degradation products (arrows). (E) Focal disruption of the normal
sarcomere structures (arrow) and autophagic vacuoles appearing together. (F) Large amorphous and partly fibrillar protein aggregates (arrows).
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Figure 4 Immunohistochemical staining of muscle biopsy from Patient III:1 and western blot analysis of Patients III:1 and III:5
in Family 1. (A) a-Sarcoglycan appears focally accumulated in the subsarcolemmal region (arrow heads) and also internally (arrows) in several
fibres. (B) Caveolin-3 shows variable and reduced staining at the sarcolemma (arrow heads) compared to a control (inset) and is also located in
the interior of some fibres (arrows). (C) Dystrophin is distributed diffusely in the interior of several fibres (arrows) in the same region as illus-
trated in A. (D) Desmin is accumulated in the subsarcolemmal region in many fibres (arrows). (E) LAMP2 is present in association with several
vacuoles indicating lysosomal origin (arrows). (F) LC3 is upregulated and present in the interior of some fibres (arrows). (G) Supervillin is com-
pletely absent compared to controls where it can be detected mainly in the sarcolemmal region (arrows). (H) Western blot analysis showing that
supervillin is present in two isoforms, 250 kDa and 205 kDa, respectively, in controls but is completely absent in Patients III:1 and III:5. No trun-
cated proteins were detected in the patients.
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In Family 2, a homozygous frameshift mutation in exon
18, c.3578_3579del, p.Val1193Glufs*46 in SVIL was iden-
tified (Fig. 7B and D). The mutation is absent from current
human variation databases and is predicted to lead to a pre-
mature stop codon. No other obvious pathogenic variants
were detected in genes previously linked to muscular
diseases.
Protein expression of supervillin was studied by western
blot analysis of skeletal muscle tissue in all four patients
(Figs 4H, 6H and Supplementary Fig. 3), using antibodies
with epitopes proximal to the truncating mutations. These
analyses revealed a total absence of the full-length protein in
affected patients whereas control samples showed two bands
at 205 kDa and 250 kDa, respectively.
Figure 5 Biopsy from the deltoid muscle of Patient III:2 in Family 2, as visualized by light (A–C) and electron microscopy
(D–G). (A) A considerable number of partially atrophic lobulated muscle fibres with pointed, occasionally cap-like subsarcolemmal deposits
(arrows) (H&E). (B) Prominent oxidative enzyme activity in these fibres (arrows) (NADH). (C) Atrophic lobulated fibres are almost exclusively
type 1 fibres (arrows); no neurogenic pattern is observed (mATPase at pH 9.4). (D) Subsarcolemmal accumulation of degraded myofibrils, glyco-
gen, pleomorphic material and autophagy-associated (arrows) organelles. (E) Heterogeneous lipoprotein deposits including maturing lipofuscin
(arrows). (F) Sporadically, nemaline rods are seen (arrow). (G) Three rods in transverse section (arrows).
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Figure 6 Immunohistochemical staining and western blot analysis of muscle biopsy from Patient III:3 in Family 2. (A)
a-Sarcoglycan immunoreactivity of the pointy sarcolemma-associated structures in the lobulated muscle fibres (arrowheads) and internally in
some fibres (arrows). (B) Irregular, reduced caveolin-3 staining mostly of smaller, partially atrophic fibres (arrowheads). (C) Abnormal non-sarco-
lemmal dysferlin immunoreactivity in several fibres (arrows). Subsarcolemmal accumulation of desmin (arrows) (D) and LC3 (arrows) (E) immu-
noreactivity in affected partially atrophic fibres. (F) LC3-positive granular and vacuolar structures (arrows) were also present in muscle fibres of
normal size and in hypertrophic fibres. (G) Subsarcolemmal p62-immunoreactive subsarcolemmal material in affected lobulated fibres and occa-
sional strongly stained p62-positive autophagic vacuoles (arrows). (H) Selected immunoblot results. 1 = index case; X and K = control cases.
Scale bar = 40 mm in A–C, 25 mm in D–G.
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Figure 7 Pedigrees and molecular genetics. (A) Pedigree of Family 1. (B) Pedigree of Family 2. (C) Sequencing chromatograms demon-
strating the homozygous mutation identified in Family 1 on genomic DNA, c.4812C4A; p.Tyr1604*. (D) Sequencing chromatograms demon-
strating the homozygous mutation identified in Family 2 on genomic DNA, c.3578_3579del; p.Val1193Glufs*46. (E) Overview of the protein
structure of supervillin isoform 2 (SV2, p250) and localization of the SVIL mutations described in this study. AR = androgen receptor; FA = focal
adhesion; M = mutated sequence; N = normal sequence.
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Discussion
We describe four patients from two families with a distinct
myopathy and provide evidence that homozygous loss-of-
function mutations in the SVIL gene cause a human cardiac
and skeletal muscular disorder. In Family 1, a nonsense mu-
tation (c.4812C4A; p.Tyr1604*) and in Family 2 a 2-bp
deletion resulting in a frameshift and premature stop codon
(c.3578_3579del; p.Val1193Glufs*46) were identified. Both
reported mutations were shown to exert a loss-of-function
effect. The mutations segregated with the disorder in both
families, and none of the mutations has so far been identified
in genome aggregation databases such as gnomAD. No
homozygous loss-of-function mutations in SVIL have been
reported in a large cohort of more than 60 000 unrelated
individuals listed in the gnomAD database, suggesting that
carriers of homozygous loss-of-function mutations of SVIL
show phenotypic abnormalities and were therefore not
included in the underlying large sequencing studies. This is
also supported by a low ratio [0.26 (0.19–0.36, 90% confi-
dence interval)] of the observed/expected number of loss-of-
function mutations in that gene according to genome aggre-
gation data (Karczewski et al., 2019). The c.4812C4A;
p.Tyr1604* mutation undergoes nonsense-mediated mRNA
decay shown by PCR experiments, and loss of full-length
supervillin proteins was shown in muscle tissue from both
affected families. In the Genotype-Tissue Expression (GTEx)
Portal Database (http://www.gtexportal.org) SVIL shows the
highest expression in skeletal muscle, followed by other
organs containing smooth muscle cells and cardiac muscle
(Supplementary Fig. 2A), supporting a role for this protein
in muscle. In non-muscle tissues, supervillin mRNAs are
most abundantly expressed in thyroid gland, salivary gland
and bone marrow, while expression in brain and liver is low
(Pope et al., 1998).
A wide neck and variable hypertrophy of trapezius and
other back muscles were characteristic features of the
patients in both families, together with moderately elevated
creatine kinase levels. However, phenotypic differences were
observed between the two families. Evidence of cardiac in-
volvement but only mild contractures were present in Family
1. Family 2 showed progressive contractures and muscle
stiffness, but only subclinical cardiac involvement in the
form of slight left ventricular hypertrophy and elevated NT-
proBNP. These differences in the intra- and interfamilial clin-
ical presentation and age at onset are well known for other
muscular disorders, for example in Bethlem myopathy (con-
tractures; Bonnemann, 2011) or limb-girdle muscular dystro-
phies (cardiac involvement; Hermans et al., 2010). Our
patients did not show other obvious clinical manifestations
in organs containing smooth muscle cells (e.g. gastrointes-
tinal symptoms). These results are consistent with functional
overlap between supervillin and other proteins, as docu-
mented in non-muscle cells (Crowley et al., 2009; Smith
et al., 2013).
Muscle biopsies from both families revealed striking simi-
larities and showed signs of a structural myopathy with
numerous lobulated type 1 muscle fibres and myofibrillar
alterations. Autophagic vacuoles, as well as frequent and ex-
tensive deposits of lipoproteins were observed as signs of
altered proteostasis and impaired autophagy. The distinct
histological and ultrastructural findings in both families sug-
gest that this subtype of myopathy may be recognizable
from muscle biopsies.
Supervillin is a large multi-domain protein (Fig. 7E). At
least five different isoforms arising from differential splicing
of 35 coding exons have been described (Chen et al., 2003,
2017; Oh et al., 2003; Gangopadhyay et al., 2004; Fang
and Luna, 2013). In non-muscle cells, the most abundant
isoform is a 205-kDa protein that is encoded by 31 exons
(SV1) (Pestonjamasp et al., 1997). In cardiac and skeletal
muscle, the most prominently expressed isoform is supervil-
lin (SV2), which is the longest known muscle-specific iso-
form with a molecular mass of 250 kDa (Pope et al., 1998;
Oh et al., 2003) (Supplementary Fig. 2B). The SVIL SV2
cDNA contains an initial muscle-specific 50 leader sequence
and four additional coding exons, which result in the N-ter-
minal insert of the muscle specific amino acids 276–669 and
750–781 (Oh et al., 2003). The locations of the mutations
in our families, as well as our western blot data, suggest that
all isoforms of supervillin are disrupted. Supervillin co-local-
izes with F-actin, vinculin and non-muscle myosin II at the
membrane in myoblasts, and the protein is localized at the
ends of differentiating myotubes (Oh et al., 2003). The N-
terminus common to supervillin SV1 and SV2 binds directly
to smooth and non-muscle myosin II heavy chains and
increases myosin II contractility (Chen et al., 2003;
Takizawa et al., 2007; Bhuwania et al., 2012; Edelstein
et al., 2012). A sequence in supervillin that is interrupted by
the second muscle-specific insert regulates focal adhesion dy-
namics in non-muscle cells; its functionality in muscle is un-
known (Takizawa et al., 2006). Non-muscle and muscle
isoforms share a central, conserved sequence that transacti-
vates the androgen receptor (Ting et al., 2002). Highly con-
served SVIL-encoded C-terminal sequences interact with the
C-terminus of nebulin and thus could attach supervillin
(SV2) directly to the Z-line (Lee et al., 2008). A previous
study (Spinazzola et al., 2015) has shown a physical inter-
action either via direct interaction or indirect association be-
tween the intracellular portion of c-sarcoglycan and the C-
terminus of supervillin (SV2) (Fig. 7E). Furthermore, the
muscle-specific insert of supervillin binds to dystrophin
(Fig. 7E) (Spinazzola et al., 2015), and supervillin (SV2) and
dystrophin co-localize at costameres in skeletal muscle (Oh
et al., 2003). The supervillin (SV2) muscle-specific domain
also contains sequences homologous to those in supervillin
SV3 (expressed in smooth muscle) that activate ERK signal-
ling (Gangopadhyay et al., 2009). Thus, supervillin (SV2)
may coordinate both Z-line attachment to sarcomeres and
signalling cross-talk between the dystrophin-glycoprotein
complex and integrin-associated sarcomeric domains and be-
tween these domains and the nucleus. Such multiple func-
tions of supervillin isoforms with both signalling and
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structural properties may explain the characteristic muscle
phenotypes in our patients.
In a proteomic study applying laser microdissection and
mass spectrometry analyses on a protein aggregate myop-
athy caused by mutations in myotilin, supervillin was identi-
fied among the accumulated proteins (Maerkens et al.,
2016). Most of the accumulated proteins in the aggregates
were Z-disc associated proteins followed by sarcolemmal
and extracellular matrix proteins. It is therefore not surpris-
ing that supervillin was identified in the aggregates, probably
because it binds to several of the accumulated proteins such
as dystrophin and sarcoglycans. These results emphasize the
role of supervillin as a binding partner to other structural
proteins and thus probably functioning as part of a system
keeping the essential components of muscle cells in their cor-
rect position. Complete loss of supervillin as indicated from
the muscle biopsies from the affected patients was accompa-
nied by alterations of major sarcolemma-associated proteins
like caveolin-3, dystrophin, dysferlin and a-sarcoglycan as
shown by immunohistochemistry. This may lead to changes
of the muscle fibre cytoskeleton causing myofibrillar disarray
and thus increased breakdown of myofibrillar proteins,
resulting in altered proteostasis and impaired autophagy.
The heart involvement in Family 1 was mild and was
mainly manifested by troponin T leakage and ECG abnor-
malities. By applying the Objective Prioritization Enhanced
Novelty (OPEN) machine learning approach, SVIL was
identified as a prioritized gene for dilated cardiomyopathy
(Deo et al., 2014). Using this approach SVIL was identified
among three prioritized genes that were not previously asso-
ciated with cardiac disease. A morpholino knock-down of
SVIL in a zebrafish model demonstrated a significant de-
crease in atrial conduction velocity (Deo et al., 2014).
Results from these studies focusing on the heart support the
concept that supervillin is of importance for normal cardiac
function, but the exact physiological role of supervillin in
the heart remains to be established.
In conclusion, this study reveals that biallelic loss-of-func-
tion mutations in SVIL cause a new structural myopathy
with prominent lobulated type 1 fibres, myofibrillar disinte-
gration and signs of altered proteostasis and impaired
autophagy. Essential clinical signs of this new disorder in-
clude muscle pain and slowly progressive stiffness, contrac-
tures of varying degree, distinct anomalies of neck and
shoulder girdle and mild cardiac involvement. The patho-
logical changes emphasize the role of supervillin in maintain-
ing the structural integrity of the muscle fibres. Although
there were some striking phenotypic similarities between
affected individuals from two nonrelated families, identifica-
tion of additional patients will reveal the full phenotypic
spectrum of this entity.
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